JNCE
Income statement / Annual
Last year (2022), Jounce Therapeutics, Inc.'s total revenue was $82.00 M,
an increase of 204.75% from the previous year.
In 2022, Jounce Therapeutics, Inc.'s net income was -$50.92 M.
See Jounce Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$82.00 M |
$26.91 M |
$62.34 M |
$147.87 M |
$65.20 M |
$71.64 M |
$37.20 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$82.00 M
|
$26.91 M
|
$62.34 M
|
$147.87 M
|
$65.20 M
|
$71.64 M
|
$37.20 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
| Research and Development Expenses |
$103.27 M
|
$88.98 M
|
$78.69 M
|
$67.14 M
|
$70.05 M
|
$67.80 M
|
$34.90 M
|
$22.13 M
|
$11.24 M
|
| General & Administrative Expenses |
$30.97 M
|
$28.98 M
|
$28.77 M
|
$27.92 M
|
$26.44 M
|
$23.06 M
|
$16.76 M
|
$8.27 M
|
$4.97 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$30.97 M
|
$28.98 M
|
$28.77 M
|
$27.92 M
|
$26.44 M
|
$23.06 M
|
$16.76 M
|
$8.27 M
|
$4.97 M
|
| Other Expenses |
$1.46 M
|
$199,000.00
|
$1.29 M
|
$4.05 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$134.24 M
|
$117.96 M
|
$107.46 M
|
$95.06 M
|
$96.50 M
|
$90.86 M
|
$51.66 M
|
$30.40 M
|
$16.21 M
|
| Cost And Expenses |
$134.24 M
|
$117.96 M
|
$107.46 M
|
$95.06 M
|
$96.50 M
|
$90.86 M
|
$51.66 M
|
$30.40 M
|
$16.21 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.09 M
|
$2.83 M
|
$3.40 M
|
$3.85 M
|
$3.83 M
|
$4.42 M
|
$1.94 M
|
$1.47 M
|
$1.11 M
|
| EBITDA |
-$50.16 M |
-$91.06 M |
-$45.12 M |
$52.82 M |
-$23.50 M |
-$11.99 M |
-$11.76 M |
-$27.06 M |
-$9.41 M |
| EBITDA Ratio |
-0.61
|
-3.38
|
-0.72
|
0.36
|
-0.36
|
-0.17
|
-0.32
|
0
|
0
|
| Operating Income Ratio |
-0.64
|
-3.38
|
-0.72
|
0.36
|
-0.48
|
-0.27
|
-0.39
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.46 M
|
$199,000.00
|
$1.29 M
|
$4.05 M
|
$3.96 M
|
$2.81 M
|
$763,000.00
|
$1.86 M
|
$5.70 M
|
| Income Before Tax |
-$50.78 M
|
-$90.86 M
|
-$43.83 M
|
$56.87 M
|
-$27.33 M
|
-$16.41 M
|
-$13.70 M
|
-$28.53 M
|
-$10.52 M
|
| Income Before Tax Ratio |
-0.62
|
-3.38
|
-0.7
|
0.38
|
-0.42
|
-0.23
|
-0.37
|
0
|
0
|
| Income Tax Expense |
$135,000.00
|
$15,000.00
|
$14,000.00
|
$46,000.00
|
$46,000.00
|
$36,000.00
|
$763,000.00
|
$1.86 M
|
$5.70 M
|
| Net Income |
-$50.92 M
|
-$90.87 M
|
-$43.84 M
|
$56.82 M
|
-$27.38 M
|
-$16.44 M
|
-$13.70 M
|
-$28.53 M
|
-$10.52 M
|
| Net Income Ratio |
-0.62
|
-3.38
|
-0.7
|
0.38
|
-0.42
|
-0.23
|
-0.37
|
0
|
0
|
| EPS |
-0.99 |
-1.82 |
-1.24 |
1.72 |
-0.84 |
-0.55 |
-0.45 |
-1.54 |
-0.48 |
| EPS Diluted |
-0.99 |
-1.82 |
-1.24 |
1.66 |
-0.84 |
-0.55 |
-0.45 |
-1.54 |
-0.48 |
| Weighted Average Shares Out |
$51.68 M
|
$49.93 M
|
$35.43 M
|
$33.08 M
|
$32.57 M
|
$30.06 M
|
$30.16 M
|
$18.52 M
|
$22.09 M
|
| Weighted Average Shares Out Diluted |
$51.68 M
|
$49.93 M
|
$35.43 M
|
$34.29 M
|
$32.57 M
|
$30.06 M
|
$30.16 M
|
$18.52 M
|
$22.09 M
|
| Link |
|
|
|
|
|
|
|
|
|
